Industry News

22 November 2025

BE’s New 14-Valent Pneumococcal Vaccine Secures WHO Pre-Qualification

Biological E. Limited (BE), one of India’s leading vaccine and pharmaceutical manufacturers, has announced a major milestone with the World Health Organisation (WHO) granting Pre-qualification (PQ) status to its 14-valent Pneumococcal Conjugate Vaccine, PNEUBEVAX 14 (BE-PCV-14). This achievement marks the company’s 11th vaccine to enter the WHO PQ portfolio, strengthening its presence among global immunisation suppliers.

18 November 2025

AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India

AstraZeneca Pharma India Limited a leading science-led biopharmaceutical company and Sun Pharmaceutical Industries Limited today announced a second brand partnership for Sodium Zirconium Cyclosilicate in India.

17 November 2025

Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar

Sandoz, the global leader in affordable medicines, today announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by Polpharma Biologics, TYRUKO® is the first and only US Food and Drug Administration (FDA) approved natalizumab biosimilar for the treatment of relapsing forms of multiple sclerosis (MS).

17 November 2025

Lupin’s Nagpur Unit-1 Clears U.S. FDA Pre-Approval Inspection with No Observations

Global pharmaceutical company Lupin Limited announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a product-specific pre-approval inspection at its Unit-1 oral solid dosage facility in Nagpur.

17 November 2025

Merck to Acquire Cidara Therapeutics, Inc

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for 221.50 USD per share in cash, for a total transaction value of approximately 9.2 billion USD.

14 November 2025

Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91

Global pharma leader Lupin Limited announced that it has achieved an S&P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28.

14 November 2025

Alkem Laboratories Posts Strong Q2 FY26 - Sees 17% Revenue Growth, 22% Rise in EBITDA

Alkem Laboratories Ltd. reported robust performance for the second quarter ended 30 September 2025. The company recorded revenues of Rs. 40,010 million, up by 17.2 % year-on-year.

14 November 2025

Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration USFDA for Diroximel Fumarate delayed-release capsules, 231 mg.

12 November 2025

Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab

Sandoz the global leader in affordable medicines, today announced the signing of a global license agreement to commercialize a proposed biosimilar of oncology medicine pertuzumab.

11 November 2025

Zydus receives approval from China’s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg

Zydus Lifesciences Limited has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg.

Search

BE’s New 14-Valent Pneumococcal Vaccine Secures WHO Pre-Qualification

RECOMMENDED POSTS

Subscribe with us

Jobs by Category